“Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch Vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison”. 2026. SKIN The Journal of Cutaneous Medicine 10 (2): s738. https://doi.org/10.25251/0bwr4a20.